Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

MLA

Amstutz, Ursula, et al. “Recommendations for HLA-B*15:02 and HLA-A*31:01 Genetic Testing to Reduce the Risk of Carbamazepine-Induced Hypersensitivity Reactions.” Epilepsia, vol. 55, no. 4, Apr. 2014, pp. 496–506. EBSCOhost, https://doi.org/10.1111/epi.12564.

APA

Amstutz, U., Shear, N. H., Rieder, M. J., Hwang, S., Fung, V., Nakamura, H., Connolly, M. B., Ito, S., & Carleton, B. C. (2014). Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia, 55(4), 496–506. https://doi.org/10.1111/epi.12564

Chicago

Amstutz, Ursula, Neil H Shear, Michael J Rieder, Soomi Hwang, Vincent Fung, Hidefumi Nakamura, Mary B Connolly, Shinya Ito, and Bruce C Carleton. 2014. “Recommendations for HLA-B*15:02 and HLA-A*31:01 Genetic Testing to Reduce the Risk of Carbamazepine-Induced Hypersensitivity Reactions.” Epilepsia 55 (4): 496–506. doi:10.1111/epi.12564.